A phase I vaccination study with tyrosinase in patients with stage II melanoma using recombinant modified vaccinia virus Ankara (MVA-hTyr)

Overview of attention for article published in Cancer Immunology, Immunotherapy, December 2004

Altmetric Badge

About this Attention Score

In the top 25% of all research outputs scored by Altmetric
High Attention Score compared to outputs of the same age (81st percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

patent: 12 patents

Citations

dimensions_citation: 53 Dimensions

Readers on

mendeley: 41 Mendeley

Summary Patents Dimensions citations

So far, Altmetric has seen 12 patents that reference this research output.

Use of oil and water emulsions for increasing B cell responses with modified Vaccinia…

Grant US-10653766-B2

United States of America

Compositions and methods

Application US-10286060-B2

United States of America

Methods and compositions using Listeria for enhancing immunogenicity by prime boost

Grant US-9878024-B2

United States of America

MODIFIED VACCINIA ANKARA VIRUS VARIANT

Grant EP-1335987-B2

European Patent Office

Methods and compositions using listeria for enhancing immunogenicity by prime boost

Grant US-9198960-B2

United States of America

Methods and compositions for inducing an immune response to EGFRvIII

Grant US-9200057-B2

United States of America

Methods and compositions using listeria for adjuvant treatment of cancer

Grant US-9161974-B2

United States of America

Methods and compositions using Listeria for enhancing immunogenicity by prime boost

Grant US-8926993-B2

United States of America

Modified Vaccinia ankara virus variant

Grant US-8268329-B2

United States of America

Modified Vaccinia Ankara virus variant

Grant US-8268325-B2

United States of America

Modified Vaccinia Ankara virus variant

Grant US-7939086-B2

United States of America

Modified Vaccinia Ankara virus variant

Grant US-7923017-B2

United States of America